10times
06 Oct 2020Ended

Oncolytic Virus Immunotherapy

About 18Sessions 12SpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

06 Oct 2020
+1 more editions

Frequency

Quarterly
Next edition likely in Jan 2021
Claim event to edit details

Oncolytic virotherapy (OV) represents an exciting new area of cancer treatment by exploiting a virus’s ability to selectively replicate and kill .. Read more tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following significant scientific breakthroughs in mechanisms of action, efficacy, combination therapies, delivery, and investment from big pharma players such as Pfizer, Amgen, Merck, Johnson and Johnson.CHI’s Oncolytic Virus Immunotherapy conference brings together leading industry and academic leaders to discuss the critical steps needed to accelerate oncolytic virus immunotherapy, from delivery to combination therapy strategies; virus engineering to manufacturing and commercialization..

1   Different Located Editions
Boston, USA 10 - 11 Aug 2020
19 Followers
Tue, 06 Oct
Session
FEATURED PRESENTATION: Lessons Learned from Preclinical and Clinical Development of Retroviral Replicating Vectors
Noriyuki Kasahara, MD, PhD
Noriyuki Kasahara, MD, PhD Professor
Tue, 06 Oct
Session
Targeting Tumor Escape with Mechanism-Based Oncolytic Viroimmunotherapy
Richard Vile, PhD
Richard Vile, PhD Professor
Tue, 06 Oct
Session
Rational Engineering of Recombinant Modified Vaccinia Virus Ankara to Enhance Both Innate and Adaptive Immunity for Cancer Immunotherapy
Liang Deng, MD, PhD
Liang Deng, MD, PhD Associate Member/Laboratory Head
Tue, 06 Oct
Break
Session Break - View Our Virtual Exhibit Hall
Tue, 06 Oct
Session
Integrating Oncolytic Viruses into Combination Therapy for Cancer
Howard L. Kaufman, MD
Howard L. Kaufman, MD Head, R&D, Immuneering Corp.; Clinical Associ..
Tue, 06 Oct
Session
Combination with Oncolytic Adeno-Immunotherapy and CAR T Cells for Advanced Solid Tumors
Masataka Suzuki, PhD
Masataka Suzuki, PhD Assistant Professor
Tue, 06 Oct
Session
Oncolytic HSV Combinations; Sometimes They Work
Samuel D. Rabkin, PhD
Samuel D. Rabkin, PhD Professor
Tue, 06 Oct
Session
ONCOS-102: Clinical Results from Melanoma and Mesothelioma Combination Trials
Erik Digman Wiklund, PhD
Erik Digman Wiklund, PhD Chief Business Officer
Tue, 06 Oct
Break
Session Break – View Our Virtual Exhibit Hall
Tue, 06 Oct
Session
Engineering the Immune Response to Blaze a Trail for Oncolytic Immunotherapy
Stephen J. Russell, MD, PhD
Stephen J. Russell, MD, PhD CEO
Tue, 06 Oct
Session
Next-Generation Oncolytic Immuno-Gene Therapy Based on HSV
Robert Coffin, PhD
Robert Coffin, PhD CEO & Founder
Tue, 06 Oct
Session
Impact of Oncolytic HSV on NOTCH Signaling
Balveen Kaur, PhD
Balveen Kaur, PhD Professor, Vice Chair, Research
Tue, 06 Oct
Break
Session Break - View Our Virtual Exhibit Hall
Tue, 06 Oct
Session
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Lorena Lerner, PhD
Lorena Lerner, PhD Vice President
Tue, 06 Oct
Session
PANEL DISCUSSION: Current Challenges in OV Development
Tue, 06 Oct
Break
Session Break - View Our Virtual Exhibit Hall
Tue, 06 Oct
Session
Interactive Breakout Discussions - View Our Virtual Exhibit Hall
Tue, 06 Oct

Close of Oncolytic Virus Immunotherapy Conference
Speaker
Noriyuki Kasahara, MD, PhD

Noriyuki Kasahara, MD, PhD

Professor
Speaker
Richard Vile, PhD

Richard Vile, PhD

Professor
Speaker
Liang Deng, MD, PhD

Liang Deng, MD, PhD

Associate Member/Laboratory Head
Speaker
Howard L. Kaufman, MD

Howard L. Kaufman, MD

Head, R&D, Immuneering Corp.; Clinical Associate, Division of Surgical...
Visitor/General
1499 USD Commercial
799 USD Academic, Government, Hospital Affiliated
  • Share your Experience
  • Organizer
Logo Follow Company

Cambridge Healthtech Institute

USA 204 Total Events / 72 Upcoming Events

More Events From The Organizer